SynthesisEuropean journal of pediatrics2018
Development of minimum standards of care for juvenile localized scleroderma.
Synthesis in European journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Article
- Review
- Long-term follow-up of linear scleroderma en coup de sabre in children with central nervous system involvement.Frontiers in immunology · 2026Article
- Article
- Article
- Linear morphea: a persistent bruise on the temple of a 9-year-old boy.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.Journal of clinical medicine · 2024Review
- Juvenile Scleroderma.Indian journal of pediatrics · 2024Review
- [Juvenile localized scleroderma].Dermatologie (Heidelberg, Germany) · 2024Review
- Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).Clinical rheumatology · 2023Article
- Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review.Archives of dermatological research · 2023Article
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- 3D stereophotogrammetry in children and adolescents with Scleroderma En Coup De Sabre/Parry-Romberg Syndrome: Description of a novel method for monitoring disease progression.Skin health and disease · 2022Article
- Parry Romberg disease with En Coup de Sabre Scleroderma: Effect of tocilizumab on periodontal bone inflammation.Journal of scleroderma and related disorders · 2021Article
- Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centre.Journal of scleroderma and related disorders · 2021Article
- Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma.AMRC open research · 2021Article
- Treatment in Juvenile Scleroderma.Current rheumatology reports · 2020Review
- Overview of Juvenile localized scleroderma and its management.World journal of pediatrics : WJP · 2020Review
- Linear Scleroderma of the Head - Updates in management of Parry Romberg Syndrome and En coup de sabre: A rapid scoping review across subspecialties.European journal of rheumatology · 2020Article
- Update on the Systemic Treatment of Pediatric Localized Scleroderma.Paediatric drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile localized scleroderma (jLS), also known as morphea, is an orphan disease. Pediatric guidelines regarding diagnosis, assessment, and management are lacking.Our objective was to develop minimum standards of care for diagnosis, assessment, and management of jLS. A systematic review was undertaken to establish the pediatric evidence for assessment and monitoring of jLS. An expert panel, including members of the Pediatric Rheumatology European Society (PRES) Scleroderma Working Group, were invited to a consensus meeting where recommendations were developed based on evidence graded by the systematic review and, where evidence was lacking, consensus opinion. A nominal technique was used where 75% consensus was taken as agreement. Recommendations for diagnosis, assessment, and management were developed. Due to a lack of pediatric evidence, these were primarily consensus driven. Careful assessment for extra-cutaneous manifestations including synovitis, brain involvement, and uveitis were key features together with joint assessments between Dermatology and Rheumatology to improve and standardize care.
conclusionManagement of jLS is varied. These recommendations should help provide standardization of assessment and care for those with this rare and potentially debilitating condition. What is Known: • Children with juvenile localized scleroderma (jLS) are managed by a number of specialties including pediatric rheumatologists and dermatologists, sometimes in shared clinics. Studies have shown that management varies considerably and that there are notable differences between specialties [1]. • There is very little published guidance on management of jLS. What is new: • These recommendations aim to standardize diagnosis, assessment, and management through review of pediatric evidence and consensus agreement. • Joint review of patients by both pediatric rheumatologists and dermatologists is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.